HGSI Related
-
GlaxoSmithKline (GSK) Announces Results of Initial Tender Offer for Human Genome Sciences (HGSI)
-
Amgen (AMGN) Said to Make $7B Bid for Human Genome (HGSI) in 2010
-
Maxim Cuts Human Genome Sciences (HGSI) to Hold
-
Stocks with implied volatility movement; UA HGSI
-
Top 10 News Items 7/16-7/20: Bernanke Points to Slower Than Expected Growth; A Wave of Tech Earnings; Marissa Mayer Named New Yahoo! CEO
-
Summer Street Downgrades Human Genome Sciences (HGSI) to Neutral
-
JPMorgan Downgrades Human Genome Sciences (HGSI) to Neutral
-
Baird Downgrades Human Genome Sciences (HGSI) to Neutral; Story Now Played Out
-
Notable Mergers and Acquisitions of the Day 07/16: (GSK)/(HGSI) (PRX) (MMUS) (CONM)
-
Shares of Human Genome Sciences (HGSI) resume trading up ~5%
-
Shares of Human Genome Sciences (HGSI) to resume trading at 9:45am ET
-
Pre-Open Winners 7/16: (PRX) (AUTH) (HGSI) Higher (more...)
-
Glaxo (GSK) Confirms Offer for Human Genome (HGSI), Deal Valued at $14.25/Share in Cash
-
Human Genome Sciences Inc. (HGSI) acquired by GSK for $14.25/share
-
Human Genome Sciences Inc. (HGSI) halted news pending
-
Human Genome Sciences (HGSI) Agrees to $14/Share Takeover from GSK (GSK) - Reports
-
Human Genome (HGSI) Announces Resubmission of Raxibacumab BLA; PDUFA Date Set for Dec. 15th
-
Pre-Open Winners 7/9: (FX) (AGP) (CNC) Higher (more...)
-
A Celgene (CELG) / Human Genome Sciences (HGSI) Deal Seen as Unlikely
-
Human Genome (HGSI) volatility decreases into GlaxoSmithKline’s July 20 expiration of tender
-
S&P Biotech EFT (XBI) Pops on Amylin (AMLN) Buyout News
-
Human Genome (HGSI) Says Less than 1% of Shares Tendered in Glaxo (GSK) Offer
-
Glaxo (GSK) Extends $13/Share Tender for Human Genome (HGSI)
-
Human Genome (HGSI) Could Get 15% More in Takeover Bid - Analyst
-
Pre-Open Winners 6/15: (YPF) (LNG) (NAV) (more...)
-
Is Human Genome (HGSI) Getting Desperate for a Deal?
-
ATTENTION, GLAXO (GSK): Human Genome's (HGSI) Cut-Off Date is July 16th, Will Provide Details to Interested Parties
-
Human Genome Sciences (HGSI) Calls It; Says July 16th Deadline for Bids (GSK)
-
JMP Securities Upgrades Human Genome Sciences (HGSI) to Market Perform
-
BioMarin (BMRN) Higher as Takeover Chatter Swirls
-
Notable Mergers and Acquisitions of the Day 06/08: (CHK)/(CHKM) (HGSI)/(GSK) (CTFO)
-
Human Genome (HGSI) Rejects $13/Share Bid from Glaxo (GSK); Calls It 'Inadequate'
-
Human Genome (HGSI) Comments on GlaxoSmithKline's (GSK) Announcement to Extend Tender Offer
-
UPDATE: GlaxoSmithKline (GSK) Extends Tender Offer for Human Genome (HGSI) to June 29th
-
UPDATE: Human Genome (HGSI) Rejects GSK's (GSK) $13/Share Offer
-
Stocks with implied volatility below IV index mean; HGSI AMLN
-
Human Genome (HGSI) Shares Moving as Reuters Says Glaxo (GSK) Wants to Replace Entire Board
-
Stocks with implied volatility below IV index mean; HGSI ARBA
-
Notable Analyst Rating Changes 05/24: (PPG) (WPI) (DUK) Upgraded; (BHI) (HGSI) (COG) Downgraded
-
BMO Capital Downgrades Human Genome Sciences (HGSI) to Market Perform
-
Glaxo (GSK) Comments on Human Genome (HGSI) Bid Rejection; Will Continue with $13/Share Tender
-
Human Genome Sciences (HGSI) Unanimously Rejects GlaxoSmithKline (GSK) Offer
-
Barclays Maintains an 'Equalweight' on Human Genome Sciences (HGSI); Looking At $15/Share For GSK To Seal The Deal
-
Notable Analyst Rating Changes 05/10: (TPX) (PRU) (KERX) Upgraded; (VRTX) (HGSI) (ORCL) Downgraded
-
Leerink Swann Downgrades Human Genome Sciences (HGSI) to Market Perform; Limited Visibility
-
Notable Mergers and Acquisitions of the Day 05/09: (BBBY)/(CPWM) (GSK)/(HGSI) (NKBP)
-
Human Genome Sciences (HGSI) to Review Offer from Glaxo (GSK)
-
Pre-Open Movers 5/9: (SODA) (DMD) (DF) Higher; (CQB) (DVA) (STEC) Lower (more...)
-
GlaxoSmithKline (GSK) Commence $13/Share Tender Offer for Human Genome Sciences (HGSI)
-
Stocks with implied volatility below IV index mean; AMLN HGSI
Back to HGSI Stock Lookup
